![PRD_000946 PRD_000946](https://data.pdbj.org/pdbjplus/data/cc/svg/23X.svg) | PRD_000946 | Name: | N~2~-acetyl-N-[(2S,3R)-4-{(1,3-benzothiazol-6-ylsulfonyl)[(2S)-2-methylbutyl]amino}-3-hydroxy-1-phenylbutan-2-yl]-L-isoleucinamide | Formula: | C30 H42 N4 O5 S2 | Description: | SYNTHETIC HIV-1 PROTEASE INHIBITOR | Definition date: | 2012-12-12 | Last modified: | 2012-12-12 |
|
![PRD_000183 PRD_000183](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000183.svg) | PRD_000183 | Name: | Microcin C7 | Formula: | C28 H49 N12 O10 S | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000947 PRD_000947](https://data.pdbj.org/pdbjplus/data/cc/svg/F72.svg) | PRD_000947 | Name: | N-{(2S,3R)-4-[(1,3-benzothiazol-6-ylsulfonyl)(cyclohexylmethyl)amino]-3-hydroxy-1-phenylbutan-2-yl}-3-hydroxybenzamide | Formula: | C31 H35 N3 O5 S2 | Description: | SYNTHETIC HIV-1 PROTEASE INHIBITOR | Definition date: | 2012-12-12 | Last modified: | 2012-12-12 |
|
![PRD_000184 PRD_000184](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000184.svg) | PRD_000184 | Name: | Microcin J25 | Formula: | C101 H140 N23 O27 | Definition date: | 2012-12-12 | Last modified: | 2013-06-03 |
|
![PRD_000948 PRD_000948](https://data.pdbj.org/pdbjplus/data/cc/svg/A69.svg) | PRD_000948 | Name: | N-{(2S,3R)-4-[(1,3-benzothiazol-6-ylsulfonyl)(3-phenylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl}-3-hydroxybenzamide | Formula: | C33 H33 N3 O5 S2 | Description: | SYNTHETIC HIV-1 PROTEASE INHIBITOR | Definition date: | 2012-12-12 | Last modified: | 2012-12-12 |
|
![PRD_000949 PRD_000949](https://data.pdbj.org/pdbjplus/data/cc/svg/F71.svg) | PRD_000949 | Name: | 3-hydroxy-N-[(2S,3R)-3-hydroxy-4-([(2S)-2-methylbutyl]{[5-(1,2-oxazol-5-yl)thiophen-2-yl]sulfonyl}amino)-1-phenylbutan-2-yl]benzamide | Formula: | C29 H33 N3 O6 S2 | Description: | SYNTHETIC HIV-1 PROTEASE INHIBITOR | Definition date: | 2012-12-12 | Last modified: | 2012-12-12 |
|
![PRD_000186 PRD_000186](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000186.svg) | PRD_000186 | Name: | EFRAPEPTIN C | Formula: | C80 H138 N18 O16 | Description: | EFRAPEPTIN C IS A LINEAR PEPTIDE, WITH ACETYLATED
(ACE) PIPECOLIC ACID (YCP) AT THE N-TERMINUS AND
A MODIFIED LEUCINE AT THE C-TERM (TLX) | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000950 PRD_000950](https://data.pdbj.org/pdbjplus/data/cc/svg/55A.svg) | PRD_000950 | Name: | N~2~-acetyl-N-[(2S,3R)-4-{(1,3-benzothiazol-6-ylsulfonyl)[(2S)-2-methylbutyl]amino}-3-hydroxy-1-phenylbutan-2-yl]-L-leucinamide | Formula: | C30 H42 N4 O5 S2 | Description: | SYNTHETIC HIV-1 PROTEASE INHIBITOR | Definition date: | 2012-12-12 | Last modified: | 2012-12-12 |
|
![PRD_000187 PRD_000187](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000187.svg) | PRD_000187 | Name: | SCYPTOLIN A | Formula: | C45 H71 Cl N8 O14 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000951 PRD_000951](https://data.pdbj.org/pdbjplus/data/cc/svg/K83.svg) | PRD_000951 | Name: | 3-hydroxy-N-[(2S,3R)-3-hydroxy-4-{[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino}-1-phenylbutan-2-yl]benzamide | Formula: | C28 H34 N2 O6 S | Description: | SYNTHETIC HIV-1 PROTEASE INHIBITOR | Definition date: | 2012-12-12 | Last modified: | 2012-12-12 |
|
![PRD_000193 PRD_000193](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000193.svg) | PRD_000193 | Name: | Capreomycin IA | Formula: | C25 H44 N14 O8 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000952 PRD_000952](https://data.pdbj.org/pdbjplus/data/cc/svg/A68.svg) | PRD_000952 | Name: | N~2~-acetyl-N-[(2S,3R)-3-hydroxy-4-{[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino}-1-phenylbutan-2-yl]-L-isoleucinamide | Formula: | C29 H43 N3 O6 S | Description: | SYNTHETIC HIV-1 PROTEASE INHIBITOR | Definition date: | 2012-12-12 | Last modified: | 2012-12-12 |
|
![PRD_000194 PRD_000194](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000194.svg) | PRD_000194 | Name: | ACTAGARDINE | Formula: | C81 H124 N20 O23 S4 | Description: | ACTAGARDINE IS A TRICYCLIC PEPTIDE. POST TRANSLATIONAL MATURATION
OF LANTIBIOTICS INVOLVES THE ENZYMIC CONVERSION OF THR AND SER INTO
DEHYDRATED AMINO ACIDS AND THE FORMATION OF THIOETHER BONDS WITH
CYSTEINE. THE THIOETHER BONDS WITH CYSTEINE RESULT IN THREE
RING STRUCTURES. THIS IS FOLLOWED BY MEMBRANE TRANSLOCATION AND
CLEAVAGE OF THE MODIFIED PRECURSOR. | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000953 PRD_000953](https://data.pdbj.org/pdbjplus/data/cc/svg/77F.svg) | PRD_000953 | Name: | N-[(2S,3R)-4-{(cyclohexylmethyl)[(4-methoxyphenyl)sulfonyl]amino}-3-hydroxy-1-phenylbutan-2-yl]-3-hydroxybenzamide | Formula: | C31 H38 N2 O6 S | Description: | SYNTHETIC HIV-1 PROTEASE INHIBITOR | Definition date: | 2012-12-12 | Last modified: | 2012-12-12 |
|
![PRD_000195 PRD_000195](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000195.svg) | PRD_000195 | Name: | Cinnamycin | Formula: | C89 H127 N25 O25 S3 | Description: | CINNAMYCIN IS A TETRACYCLIC PEPTIDE. POST TRANSLATIONAL MATURATION
OF LANTIBIOTICS INVOLVES THE ENZYMIC CONVERSION OF THR AND SER INTO
DEHYDRATED AMINO ACIDS AND THE FORMATION OF THIOETHER BONDS WITH
CYSTEINE. THE 14-19 BETA-METHYLLANTHIONINE THIOETHER BOND IS OXIDIZED
TO A SULFOXIDE. THE THIOETHER BONDS WITH CYSTEINE RESULT IN THREE
RING STRUCTURES, CROSSLINK BETWEEN SER AND LYS RESULT IN THE FOURTH
RING. THIS IS FOLLOWED BY MEMBRANE TRANSLOCATION AND CLEAVAGE OF THE
MODIFIED PRECURSOR. | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000954 PRD_000954](https://data.pdbj.org/pdbjplus/data/cc/svg/F78.svg) | PRD_000954 | Name: | 3-hydroxy-N-[(2S,3R)-3-hydroxy-4-{[(4-methoxyphenyl)sulfonyl](3-phenylpropyl)amino}-1-phenylbutan-2-yl]benzamide | Formula: | C33 H36 N2 O6 S | Description: | SYNTHETIC HIV-1 PROTEASE INHIBITOR | Definition date: | 2012-12-12 | Last modified: | 2012-12-12 |
|
![PRD_000196 PRD_000196](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000196.svg) | PRD_000196 | Name: | EPILANCIN 15X | Formula: | C145 H241 N41 O33 S3 | Description: | Epilancin 15X is a tricyclic peptide. thioether bonds with cysteine
result in three rings along the peptide chain. Post Translational
maturation of lantibiotics involves the enzymic conversion of Thr and
Ser into dehydrated amino acids and the formation of thioether bonds
with cysteine. This is followed by membrane translocation and
cleavage of the modified precursor. | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000955 PRD_000955](https://data.pdbj.org/pdbjplus/data/cc/svg/AF8.svg) | PRD_000955 | Name: | 3-hydroxy-N-{(2S,3R)-3-hydroxy-4-[(2-methylpropyl){[5-(1,2-oxazol-5-yl)thiophen-2-yl]sulfonyl}amino]-1-phenylbutan-2-yl}benzamide | Formula: | C28 H31 N3 O6 S2 | Description: | SYNTHETIC HIV-1 PROTEASE INHIBITOR | Definition date: | 2012-12-12 | Last modified: | 2012-12-12 |
|
![PRD_000197 PRD_000197](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000197.svg) | PRD_000197 | Name: | ALPHA LICHENICIDIN PREPEPTIDE | Formula: | C142 H226 N36 O41 S5 | Description: | LICHENICIDIN VK21 IS A TETRACYCLIC PEPTIDE. POST TRANSLATIONAL
MATURATION OF LANTIBIOTICS INVOLVES THE ENZYMIC CONVERSION OF THR, AND
SER INTO DEHYDRATED AMINO ACIDS AND THE FORMATION OF THIOETHER BONDS
WITH CYSTEINE. THIOETHER BONDS WITH CYSTEINE RESULT IN FOUR RINGS.
THIS IS FOLLOWED BY MEMBRANE TRANSLOCATION AND CLEAVAGE OF THE
MODIFIED PRECURSOR. | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000198 PRD_000198](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000198.svg) | PRD_000198 | Name: | BETA LICHENICIDIN PREPEPTIDE | Formula: | C133 H200 N36 O37 S4 | Description: | LICHENICIDIN VK21 IS A TETRACYCLIC PEPTIDE. POST TRANSLATIONAL
MATURATION OF LANTIBIOTICS INVOLVES THE ENZYMIC CONVERSION OF THR, AND
SER INTO DEHYDRATED AMINO ACIDS AND THE FORMATION OF THIOETHER BONDS
WITH CYSTEINE. THIOETHER BONDS WITH CYSTEINE RESULT IN FOUR RINGS.
THIS IS FOLLOWED BY MEMBRANE TRANSLOCATION AND CLEAVAGE OF THE
MODIFIED PRECURSOR. | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000199 PRD_000199](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000199.svg) | PRD_000199 | Name: | Mersacidin | Formula: | C80 H120 N20 O21 S4 | Description: | MERSACIDIN IS A TETRACYCLIC PEPTIDE. POST TRANSLATIONAL MATURATION
OF LANTIBIOTICS INVOLVES THE ENZYMIC CONVERSION OF THR, AND SER INTO
DEHYDRATED AA AND THE FORMATION OF THIOETHER BONDS WITH CYSTEINE. THE
CARBOXY-TERMINAL BETA-METHYLLANTHIONINE UNDERGOES
DECARBOXYLATION. THIOETHER BONDS WITH CYSTEINE RESULT IN FOUR
RINGS. THIS IS FOLLOWED BY MEMBRANE TRANSLOCATION AND CLEAVAGE OF THE
MODIFIED PRECURSOR. | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000959 PRD_000959](https://data.pdbj.org/pdbjplus/data/cc/svg/3OE.svg) | PRD_000959 | Name: | 4-(benzyloxy)-N-[(2S,3R)-3-hydroxy-1-{[(2S)-1-{[(3-methylthiophen-2-yl)methyl]amino}-1-oxo-4-phenylbutan-2-yl]amino}-1-oxobutan-2-yl]benzamide | Formula: | C34 H37 N3 O5 S | Definition date: | 2012-12-12 | Last modified: | 2012-12-12 |
|
![PRD_000200 PRD_000200](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000200.svg) | PRD_000200 | Name: | Nisin A | Formula: | C141 H233 N41 O38 S7 | Description: | Nisin Z is a heptacyclic peptide. Post Translational maturation of
lantibiotics involves the enzymic conversion of Thr, and Ser into
dehydrated AA and the formation of thioether bonds with cysteine.
Thioether bonds with cysteine result in five cyclic structures along
the peptide chain. This is followed by membrane translocation and
cleavage of the modified precursor. | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000201 PRD_000201](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000201.svg) | PRD_000201 | Name: | Alpha-Amanitin | Formula: | C39 H54 N10 O14 S | Description: | ALPHA-AMANITIN, IS AN 8 AMINO-ACID PEPTIDE.
THE OUTER LOOP IS FORMED BY A PEPTIDE BOND
BETWEEN THE C- AND THE N-TERMINI. THE SIDE-CHAINS
OF RESIDUES 2 AND 8 ARE LINKED TO FORM THE INNER
LOOP. | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000964 PRD_000964](https://data.pdbj.org/pdbjplus/data/cc/svg/M32.svg) | PRD_000964 | Name: | N-(benzylsulfonyl)-D-alanyl-N-[2-(aminomethyl)-5-chlorobenzyl]-L-prolinamide | Formula: | C23 H29 Cl N4 O4 S | Definition date: | 2012-12-12 | Last modified: | 2012-12-12 |
|